JP7297734B2 - 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体 - Google Patents

可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体 Download PDF

Info

Publication number
JP7297734B2
JP7297734B2 JP2020505231A JP2020505231A JP7297734B2 JP 7297734 B2 JP7297734 B2 JP 7297734B2 JP 2020505231 A JP2020505231 A JP 2020505231A JP 2020505231 A JP2020505231 A JP 2020505231A JP 7297734 B2 JP7297734 B2 JP 7297734B2
Authority
JP
Japan
Prior art keywords
domain
polypeptide chain
antibody
functional
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528758A (ja
JP2020528758A5 (enExample
Inventor
アントニオ・ランツァヴェッキア
ルカ・ピッコリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Original Assignee
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB filed Critical Institute for Research in Biomedicine IRB
Publication of JP2020528758A publication Critical patent/JP2020528758A/ja
Publication of JP2020528758A5 publication Critical patent/JP2020528758A5/ja
Priority to JP2023097920A priority Critical patent/JP2023123588A/ja
Application granted granted Critical
Publication of JP7297734B2 publication Critical patent/JP7297734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020505231A 2017-07-31 2018-07-30 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体 Active JP7297734B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023097920A JP2023123588A (ja) 2017-07-31 2023-06-14 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/069357 2017-07-31
PCT/EP2017/069357 WO2019024979A1 (en) 2017-07-31 2017-07-31 FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
PCT/EP2018/070640 WO2019025391A1 (en) 2017-07-31 2018-07-30 ANTIBODIES HAVING FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN A VARIABLE DOMAIN AND A CONSTANT DOMAIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097920A Division JP2023123588A (ja) 2017-07-31 2023-06-14 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体

Publications (3)

Publication Number Publication Date
JP2020528758A JP2020528758A (ja) 2020-10-01
JP2020528758A5 JP2020528758A5 (enExample) 2021-09-09
JP7297734B2 true JP7297734B2 (ja) 2023-06-26

Family

ID=59626578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505231A Active JP7297734B2 (ja) 2017-07-31 2018-07-30 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体
JP2023097920A Withdrawn JP2023123588A (ja) 2017-07-31 2023-06-14 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023097920A Withdrawn JP2023123588A (ja) 2017-07-31 2023-06-14 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体

Country Status (13)

Country Link
US (1) US12331108B2 (enExample)
EP (1) EP3661962A1 (enExample)
JP (2) JP7297734B2 (enExample)
KR (1) KR20200032738A (enExample)
CN (1) CN111094341A (enExample)
AU (1) AU2018311032B2 (enExample)
BR (1) BR112019028180A2 (enExample)
CA (1) CA3069265A1 (enExample)
EA (1) EA202090364A1 (enExample)
IL (1) IL272303A (enExample)
MX (1) MX2020001080A (enExample)
SG (1) SG11201911658QA (enExample)
WO (2) WO2019024979A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
BR112020018918A2 (pt) 2018-03-22 2021-01-05 Surface Oncology, Inc. Anticorpos anti-il-27 e usos dos mesmos
AU2019266042B2 (en) * 2018-05-10 2025-08-07 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
MX2020012895A (es) 2018-05-30 2021-05-27 Inst Res Biomedicine Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena.
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
EP4100434A1 (en) 2020-02-03 2022-12-14 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
TWI859420B (zh) 2020-02-26 2024-10-21 美商維爾生物科技股份有限公司 抗sars-cov-2抗體及使用其之方法
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
EP4135846A1 (en) 2020-04-14 2023-02-22 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
JP2023525039A (ja) 2020-05-08 2023-06-14 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
CA3180477A1 (en) 2020-06-12 2021-12-16 Elizabeth Alexander Antibody therapies for sars-cov-2 infection
EP4217385A2 (en) 2020-09-28 2023-08-02 VIR Biotechnology, Inc. Antibodies against sars-cov-2
CN112225807B (zh) * 2020-10-30 2021-09-07 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
JP2023551667A (ja) 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド 抗－インフルエンザ抗体及びその組合せ
KR20230135569A (ko) 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
WO2022109309A1 (en) 2020-11-23 2022-05-27 Vir Biotechnology, Inc. Broadly neutralizing antibodies against influenza neuraminidase
WO2022115486A1 (en) 2020-11-25 2022-06-02 Vir Biotechnology, Inc. Antibodies that bind to multiple betacoronaviruses
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4271715A4 (en) * 2020-12-30 2024-11-20 Wuxi Biologics Ireland Limited MULTI-SPECIFIC ANTIGEN-BINDING PROTEINS
CN112877394A (zh) * 2021-01-27 2021-06-01 南京大学 B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2022236142A2 (en) * 2021-05-07 2022-11-10 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
AU2022280767A1 (en) 2021-05-24 2024-01-18 Humabs Biomed Sa Engineered polypeptides
WO2023034866A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用
EP4444758A2 (en) 2021-12-10 2024-10-16 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US20230416406A1 (en) 2022-03-10 2023-12-28 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
JP2025522295A (ja) 2022-05-23 2025-07-15 ヒューマブス・バイオメッド・ソシエテ・アノニム インフルエンザノイラミニダーゼに対する広域中和抗体
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
EP4562034A1 (en) 2022-07-27 2025-06-04 Humabs Biomed SA Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same
WO2024215762A1 (en) 2023-04-10 2024-10-17 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2025015321A1 (en) 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
WO2016207402A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
WO2016208695A1 (ja) 2015-06-24 2016-12-29 Ｊｃｒファーマ株式会社 血液脳関門を通過する抗ヒトトランスフェリン受容体抗体
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
US20140235476A1 (en) * 2012-12-28 2014-08-21 Abbvie, Inc. Multivalent binding protein compositions and methods for identifying variants of same
HK1216894A1 (zh) * 2012-12-28 2016-12-09 Abbvie Inc. 多價結合蛋白組合物
US9814784B2 (en) 2013-01-03 2017-11-14 Celltrion, Inc. Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
US10526404B2 (en) * 2015-04-29 2020-01-07 Institute For Research In Biomedicine Multispecific anti GM-CSF antibodies
AU2016277887B2 (en) * 2015-06-18 2022-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulin single variable domain antibody against RSV prefusion F protein
AU2019266042B2 (en) * 2018-05-10 2025-08-07 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
WO2016208695A1 (ja) 2015-06-24 2016-12-29 Ｊｃｒファーマ株式会社 血液脳関門を通過する抗ヒトトランスフェリン受容体抗体
WO2016207402A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma

Also Published As

Publication number Publication date
SG11201911658QA (en) 2020-03-30
AU2018311032A1 (en) 2019-12-05
US12331108B2 (en) 2025-06-17
KR20200032738A (ko) 2020-03-26
US20200325220A1 (en) 2020-10-15
JP2020528758A (ja) 2020-10-01
WO2019025391A1 (en) 2019-02-07
AU2018311032B2 (en) 2025-01-23
EA202090364A1 (ru) 2020-06-26
IL272303A (en) 2020-03-31
MX2020001080A (es) 2020-08-06
WO2019025391A9 (en) 2020-02-13
JP2023123588A (ja) 2023-09-05
EP3661962A1 (en) 2020-06-10
CN111094341A (zh) 2020-05-01
WO2019024979A1 (en) 2019-02-07
CA3069265A1 (en) 2019-02-07
BR112019028180A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
JP7297734B2 (ja) 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体
CN114245807B (zh) Flt3l-fc融合蛋白和使用方法
US10927184B2 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
US9573988B2 (en) Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US20210315933A1 (en) Compositions and methods for tcr reprogramming using target specific fusion proteins
CN106349389B (zh) 肿瘤特异性抗egfr抗体及其应用
JP2015513394A (ja) 二重特異性キメラ抗原受容体およびその治療的使用
JP2024063211A (ja) 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング
JP2022524219A (ja) 標的指向活性遺伝子編集剤及び使用方法
JP2024112828A (ja) 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物
CN115485293A (zh) 用于her2的嵌合抗原受体和其使用方法
EA046243B1 (ru) Антитела с функциональными доменами в области изгиба между вариабельным и константым доменом
US20250353931A1 (en) Multi-specific reagent for targeted delivery of lipid nanoparticles
HK40029066A (en) Antibodies with functional domains in the elbow region between variable and constant domain
HK40040001A (en) Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase
HK40090466A (zh) 包含表达嵌合受体的细胞的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210729

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230614

R150 Certificate of patent or registration of utility model

Ref document number: 7297734

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02